Literature DB >> 6604220

Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.

M C Owen, S O Brennan, J H Lewis, R W Carrell.   

Abstract

Our previous studies predicted a functional relationship between the plasma proteins alpha 1-antitrypsin and antithrombin III. To elucidate this relationship we investigated the plasma of a 14-year-old boy who had died from an episodic bleeding disorder. A variant alpha 1-antitrypsin was identified in which the methionine at position 358 had been replaced by an arginine. This had converted the alpha 1-antitrypsin from its normal function as an inhibitor of elastase to that of an inhibitor of thrombin. This finding indicates that the reactive center of alpha 1-antitrypsin is methionine 358, which acts as a bait for elastase, just as the normal reactive center of antithrombin III is arginine 393, which acts as a bait for thrombin. The independence of the new thrombin inhibitor from heparin control explains the bleeding disorder; it also indicates that heparin normally acts directly on antithrombin III, revealing its inherent inhibitory activity. The episodic nature of the bleeding was a consequence of the mutant protein's being an acute-phase reactant, the level of which increased several-fold after trauma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604220     DOI: 10.1056/NEJM198309223091203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   176.079


  89 in total

1.  Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A.

Authors:  E Stratikos; P G Gettins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Inhibition of distant caspase homologues by natural caspase inhibitors.

Authors:  S J Snipas; H R Stennicke; S Riedl; J Potempa; J Travis; A J Barrett; G S Salvesen
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

Review 3.  Therapeutic approaches in hereditary angioedema.

Authors:  Sabina Antonela Antoniu
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

4.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

5.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

Review 6.  Recombinant natural anticoagulants: a review.

Authors:  P L Harper; J M Hermans; R W Carrell
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

7.  Alpha1-antitrypsin and the maintenance of hemostatic balance.

Authors:  Joseph Emmerich
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

8.  Albumin Redhill (-1 Arg, 320 Ala----Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site.

Authors:  S O Brennan; T Myles; R J Peach; D Donaldson; P M George
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

9.  Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin.

Authors:  L Yang; P Dinarvand; S H Qureshi; A R Rezaie
Journal:  Thromb Haemost       Date:  2014-02-13       Impact factor: 5.249

10.  Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus.

Authors:  M Watanabe; A Hirano; S Stenglein; J Nelson; G Thomas; T C Wong
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.